MoleculeMind, an artificial intelligence (AI)-empowered protein design platform based in Beijing, has reportedly raised over RMB 100 million (USD 14.58 million) in its latest financing round. The round was led by Cathay Biotech Inc. (SHA: 688065), a synthetic biology firm based in Shanghai, with contributions from Lenovo Capital and Sequoia Capital China. The proceeds will be directed towards the development of the AI protein optimization and design platform, MoleculeOS, and its application in biopharmaceutical, synthetic biology, and other industries.
MoleculeMind’s Global R&D Presence
MoleculeMind, which operates research and development centers in both the United States and China, has been at the forefront of AI-driven protein design. The company first demonstrated that deep learning can significantly enhance the accuracy of protein structure prediction, a breakthrough based on its RaptorX-Contact approach, which has been recognized and learned from by industry leaders such as DeepMind.
Innovative AI-Driven Protein Structure Prediction
Leveraging the MoleculeOS platform, MoleculeMind has developed an AI single-sequence protein structure prediction algorithm. This algorithm can directly predict protein structure from the primary sequence without relying on multiple sequence alignment (MSA) from homologous proteins. Additionally, the model and parameters used are more lightweight, making the technology more efficient and accessible for a range of applications.-Fineline Info & Tech
